Overview

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Status:
Completed
Trial end date:
2012-10-11
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in patients with symptomatic left ventricular systolic dysfunction and anemia.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Darbepoetin alfa